Mounting evidence for prediagnostic use of statins in reducing risk of lethal prostate cancer

Journal of Clinical Oncology

Volumn 32, Issue 1, 2014, Pages 1-2

  Mucci, Lorelei A ^a   Stampfer, Meir J ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

CANCER RISK; DRUG USE; EDITORIAL; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; RISK REDUCTION; MALE; MORTALITY; PROSTATIC NEOPLASMS; NOTE; PROSTATE TUMOR;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROSTATIC NEOPLASMS;

EID: 84894653633     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.2770     Document Type: Editorial

References (11)

1. Lovastatin Study Groups I Through IV: Lovastatin 5-year safety and efficacy study: Lovastatin Study Groups I through IV. Arch Intern Med 153:1079-1087, 1993
2. Platz EA, Leitzmann MF, Visvanathan K, et al: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98:1819-1825, 2006 (Pubitemid 46017933)
3. Giovannucci E, Liu Y, Platz EA, et al: Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121:1571-1578, 2007 (Pubitemid 47328718)
4. Penney KL, Stampfer MJ: The time is ripe for a randomized trial of metformin in clinically localized prostate cancer. J Clin Oncol 31:3054-3055, 2013
5. Bansal D, Undela K, D'Cruz S, et al: Statin use and risk of prostate cancer: A meta-analysis of observational studies. PLoS One 7:e46691, 2012
6. Geybels MS, Wright JL, Holt SK, et al: Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. The Prostate 73:1214-1222, 2013
7. Nielsen SF, Nordestgaard BG, Bojesen SE: Statin use and reduced cancer-related mortality. New Engl J Med 367:1792-1802, 2012
8. Margel D, Urbach DR, Lipscombe LL, et al: Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31:3069-3075, 2013
9. Grytli HH, Fagerland MW, Fosså SD, et al: Association between use of beta-blockers and prostate cancer-specific survival: A cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 64:e86-e87, 2013
10. Yu O, Eberg M, Benayoun S, et al: Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 32:5-11, 2014
11. Cholesterol Treatment Trialists' (CTT) Collaboration, Emberson JR, Kearney PM, et al: Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 7:e29849, 2012